Loading...
XSHE
300086
Market cap714mUSD
Dec 05, Last price  
11.10CNY
1D
0.82%
1Q
68.18%
Jan 2017
-20.26%
IPO
-19.81%
Name

Honz Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300086 chart
P/E
P/S
10.68
EPS
Div Yield, %
Shrs. gr., 5y
0.28%
Rev. gr., 5y
-14.06%
Revenues
473m
-36.07%
95,940,150135,846,194218,779,083314,451,808304,241,891368,780,279309,337,001408,538,464409,757,276471,474,596480,831,720882,744,8031,008,431,482921,642,902836,565,805535,745,365739,569,815472,817,734
Net income
-216m
L
34,197,59049,524,79297,577,158139,317,546022,580,53314,852,93562,092,44668,311,10546,156,62550,196,88613,366,21809,339,25210,987,504011,529,863-216,208,517
CFO
71m
+1.08%
30,589,23862,607,03893,576,12879,893,9720109,459,62678,928,79873,930,32278,297,41590,883,87118,172,221157,658,19145,059,857011,329,33629,322,90570,693,70571,459,925
Dividend
Aug 13, 20210.02 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pediatric medicines in China. It offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine. The company markets its products through a network of agents and sales terminals. The company was formerly known as HaiNan Honz Pharmaceutical Co.,Ltd. and changed its name to Honz Pharmaceutical Co., Ltd. in November 2016. Honz Pharmaceutical Co., Ltd. is headquartered in Guangzhou, China.
IPO date
May 26, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT